Here six takeaways:
1. The highest estimate sees the stock climbing to $68 within the next year.
2. The lowest estimate sees the target price at $56 over the next 12 months.
3. Analysts are also predicting that NuVasive will report $0.3 earnings per share in its next financial report.
4. The new consensus price target comes shortly after NuVasive announced its intention to acquire Ellipse Technologies for $380 million upfront cash payments.
5. The acquisition will likely accelerate NuVasive’s revenue growth toward the high single-digit range and be slightly accretive to the company’s non-GAAP diluted earnings per share for the first 12 months after the transaction.
6. The transaction is expected to close by the end of February.
More articles on devices:
K2M 2015 preliminary revenue up 16%: 5 key notes
SeaSpine preliminary Q4 revenue flat at $35M: 5 key notes
NeuroMetrix estimates its 2015 Q4 revenue at $2.7M — 5 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
